摘要
过氧化物酶体增殖物激活受体γ共激活因子1-α(peroxisome proliferator-activated receptor gamma coactivator 1-alpha,PGC-1α)属于人体内一种重要的核转录辅助激活因子,能与多种核受体及转录因子相互作用,以调控其靶基因的表达。PGC1-α在人体能量代谢中发挥着重要的作用,其参与脂肪酸氧化,肝糖异生以及调节线粒体ATP的生物合成等。研究表明PGC-1α基因多态性与Ⅱ型糖尿病、糖尿病肾病、肥胖以及冠心病等代谢性疾病的发生有着密切的关系。探究PGC-1α基因多态性与代谢性疾病的相关性有利于从基因层面检测和评估代谢类疾病的发生风险,从而实现早期发现和预防该疾病的发生,提高代谢性疾病的生存质量,延长生存期。本文拟就近五年PGC-1α参与的代谢途径和其基因多态性与代谢性疾病的相关性的研究进展做一综述。
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha(PGC-1α)is an important nuclear transcriptional coactivator in human body. Nuclear receptors and transcription factors interact to regulate the expression of their target genes. PGC1-α plays an important role in human energy metabolism, which is involved in fatty acid oxidation, hepatic gluconeogenesis and regulation of mitochondrial ATP biosynthesis.Studies have shown that PGC-1α gene polymorphism is closely related to the occurrence of metabolic diseases such as type 2 diabetes, diabetic nephropathy, obesity and coronary heart disease. Exploring the correlation between PGC-1α gene polymorphism and metabolic diseases is beneficial to detect and evaluate the risk of metabolic diseases from the genetic level, so as to realize early detection and prevention of the disease, improve the quality of life of metabolic diseases, and prolong Survival period. This article reviews the research progress of the metabolic pathways involved in PGC-1α and the correlation between its genetic polymorphisms and metabolic diseases in the recent five years.
作者
范志鹏
李玲
赵慧佳
陈彬尧
刘晓红
郝卓文
孙功鹏
董礼
乐江
吴建国
叶啟发
FAN Zhipeng;LI Ling;ZHAO Huijia;CHEN Binyao;LIU Xiaohong;HAO Zhuowen;SUN Gongpeng;DONG Li;YUE Jiang;WU Jianguo;YE Qifa(Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation;Department of Pharmacology, Basic Medical School of Wuhan University;College of Life Sciences of Wuhan University, State Key Laboratory of Virology, Wuhan 430071,Hubei, China;The 3rd Xiangya Hospital of Central South University, Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, Changsha 410013,Hunan,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2019年第10期1172-1180,共9页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
2016年湖北省技术创新专项(2016ACA155)
病毒学国家重点实验室开放研究基金资助项目(2018KF005)
湖北省卫计委药护技和管理专项(WJ2017H0024)
